

Category	Description
1. Purpose	The BCR Glomerulonephritis Committee is an initiative of the BC Renal Network (BC Renal, BCR) whose overall goal is to identify, implement and evaluate health care programs and health policy initiatives that target patients with glomerulonephritis (GN), and to ensure communication of such activities to relevant stakeholders. The BCR GN Committee falls within the mandate of the current BCR infrastructure because patients with GN have been identified as unique in that they represent a rare and high risk subpopulation of CKD patients who will benefit from provincial infrastructure support.
	A fundamental purpose of the BCR GN Committee is to integrate information, research and clinical activities, so that systematic evaluation of GN-related initiatives is possible in real time. Specifically, the BCR GN Committee will describe the number of GN cases in BC, clinical outcomes, and health utilization. The BC GN Registry, embedded within existing BCR information systems (PROMIS), has been established to facilitate data capture. As of March 1, 2013, prospective data on patients with GN in BC is being captured as of the time of kidney biopsy.
	In more specific terms, the committee's purpose is:
	• To facilitate the identification, implementation and evaluation of clinical care programs and health policy initiatives that improve the care of patients with GN in BC in a financially sustainable fashion.
	• To ensure knowledge translation of such initiatives to key stakeholders, including patients and physicians.
	• To facilitate prospective capture of important information in the BC GN Registry (e.g. clinical, laboratory, pathology, and outcome data) which is necessary to support the goals of the BCR GN Committee, and to promote data capture through a sustainable infrastructure that leverages existing resources.
	• To ensure awareness and promotion of information generated from the BCR GN Committee, and to promote research in the field of GN.
	 To monitor and provide information to the provincial renal community regarding the incidence, prevalence, outcomes, and health care utilization of patients with GN.
	• To review and report on quality of GN care in general.
2. Accountabilities	Health services specific to patients with GN.
	Educational initiatives regarding GN targeting key stakeholders.



	 Data capture and reporting on patients with GN, using the BC GN Registry.
3. Responsibilities	• To facilitate evidence-based clinical management and treatment of glomerular diseases for patients throughout the province through development and utilization of standardized tools.
	 To develop and implement a set of knowledge translation activities for physicians, patients and other stakeholders.
	 To ensure accountability and transparency regarding outcomes of patients with GN.
	• To promote research in glomerular diseases through access to:
	 Clinical trials.
	 Investigational medications.
	 Observational cohort studies.
	 To provide guidance and oversight to provincial GN initiatives that relate to the above-stated goals, and to ensure implementation of such initiatives.
	 To appoint, as necessary, work groups as the committee deems necessary to address specific initiatives related to the above-stated goals.
	 To receive, consider and act upon recommendations related to GN that are received from the above-stated sub-committees, other committees within BC Renal, and other health care providers outside of BC Renal.
	 To provide advice regarding the capture and utilization of data for patients with GN in BC.
	 To exercise, by delegation, the quality of care functions of the BC Renal Executive Committee – a regional Quality Committee approved and authorized by the Boards of the Provincial Health Services Authority and the BC Health Authorities and Providence Health Care – in respect of quality of care matters within the scope of the BCR GN Committee.
4. Deliverables	• To provide regular communication to the provincial nephrology community regarding the activities of the BCR GN Committee.
	 To provide regular updates to the BCR Executive regarding the activities of the BCR GN Committee.
	 To develop mechanisms by which regular data presentation and review can be conducted with the provincial nephrology



	community regarding the incidence, prevalence, health utilization and outcomes of patients with GN in BC.
5. Composition and Appointment Process	The BCR GN Committee shall consist of the following, to the extent possible and practical (which do not need to be mutually exclusive):
	 A member from each of the following BCR committees: Medical Advisory Committee (MAC), Pharmacy and Formulary Committee, Kidney Care Committee (KCC).
	The BCR Executive Director.
	A member from each BC health authority.
	A representative from PROMIS.
	 A representative from the BCR Analytics and Methodology team (statistician).
	• 1-2 members experienced in GN research and/or other research- related fields.
	 The BCR GN Committee Chair (who is also the GN Committee and GN Registry Medical Lead).
	Representatives from Laboratory Medicine and Pathology.
	 Representatives from Rheumatology and Obstetric Medicine (if available).
	 Other health care providers with an interest in GN, including physicians, pharmacists, IT specialists, statisticians, etc.
6. Chair and Reporting Relationships	The Medical Lead of the BCR GN Committee and GN Registry will be the Chair, reporting to the MAC and the BCR Administrative Executive group quarterly.
	The Chair will be appointed for a term of 5 years, with the right to be reappointed by a simple majority of votes under the conditions of quorum, and without limitation on the number of terms served.
7. Duties of the Chair	 Organize and chair BCR GN Committee meetings every 6 months, or as required.
	• Provide leadership for the GN Committee projects and operations.
8. Duties of the Committee Members	 Act as representatives of their respective health authority, BCR committee or other appropriate specialty groups.
	 Communicate with such groups regarding the activities of the committee.
9. Meetings	The BCR GN Committee shall meet at least every 6 months, or more frequently as needed, either in person or by teleconference.



	Notice of such meetings shall be initiated by the Chair.
	Minutes of each meeting will be kept and circulated.
	Each voting member of the committee shall attend in person or by phone at least 2/3 of all meetings. The BCR Executive Director in consultation with the Chair may remove any voting member who does not meet this attendance requirement.
	Work group meetings may be more frequent.
10. Quorum	A quorum shall be defined as the majority of the voting members present at a meeting within 20 minutes of the scheduled meeting start. Failure to meet quorum shall result in deferral of the meeting.
11. Voting	Each voting member has one vote, and must be present in person or by teleconference to vote. No votes by proxy will be allowed.
	The Chair is allowed a second vote in the event of a tie.
	All initiatives must pass by a majority of votes. The BCR Executive Director will not be a voting member.
12. Remuneration	There will be no remuneration for membership in the committee.
13. Communications	Members of the committee shall represent their health authorities, BCR committees or other specialty groups in issues related to GN.
	Members shall communicate regularly with their respective groups regarding activities of the committee.
14. BCPRA Support	Recognizing the GN Committee's data-centred and data-driven approach, BC Renal will provide the necessary project management and analytics/statistical support to the committee, its operations and projects.
	BC Renal will also provide administrative support to the committee, to facilitate the coordination and operation of the committee activities as needed under the direction of the Chair, and ensure minutes and communications are distributed to members in a timely fashion.
15. Section 51 Considerations	For its quality assurance activities for which reporting is restricted by Section 51 of the Evidence Act, the BCR GN Committee is accountable, through the Chair, to the BC Renal Executive Committee, and, subsequently, through the BC Renal Executive Director / Chair of the Executive Committee, to the PHSA Board of Directors, and each of the other BC Health Authority Boards of Directors (VCH/PHC, FHA, IHA, NHA, VIHA). Reports from the committee will be presented annually or as required: • Records created by, or produced for, the BCR GN Committee are
	restricted for use only as directed by the committee.



 Documents created by or for the BCR GN Committee are to be headed "Privileged and Confidential: For Quality Improvement Purposes", or otherwise indicated as "For Use by the BC Renal GN Committee".
 Records that are not created specifically by or for the BCR GN Committee (e.g. the original health authority record) are not restricted from disclosure by the committee, but are subject to the provisions of the Freedom of Information and Protection of Privacy Act (FIPPA), and PHSA policy on access to records.
Discussions and information shared regarding the clinical practices and quality improvements under review are held in strict confidence by committee members.
Quality reviews under the Section 51 of the BC Evidence Act shall be maintained as "Privileged and Confidential: For Quality Improvement Purposes". This part of the meeting that is performing the quality and safety assurance function shall be recorded "in camera" separately in the meeting minutes.